DS Biopharma (DS), a privately held drug discovery and development company with industry-leading expertise in lipid science, announces the launch...
Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for an omicron XBB.1.5-adapted mRNA vaccine (DS 5670) against the novel coronavirus infectious disease (COVID-19) for booster vaccination for individuals aged 12 years or older
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Eton Pharmaceuticals, Inc announced the FDA has accepted for filing the company’s new drug application (NDA) for dehydrated alcohol injection (DS 100).
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The FDA has approved the next-generation Ellipse and SJM Assura portfolio of implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy...
Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. announced that Takeda has entered into an exclusive agreement under which Takeda will secure global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).